Skip to content
10-Q

Quarterly Report

STRATA Skin Sciences, Inc. SSKN

0001140361-25-019036

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 4.17M sh
Shares Diluted Q1 2025 · Mar 31, 2025 4.17M sh
Shares Diluted restated Q1 2025 · Mar 31, 2024 3.51M sh
Capex Q1 2025 · Mar 31, 2025 $199K
Capex Q1 2025 · Mar 31, 2024 $725K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$550K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$804K
Long Term Debt Q1 2025 · Mar 31, 2025 $15.23M
Long Term Debt Q1 2025 · Dec 31, 2024 $15.19M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $6.51M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $7.26M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $5.24M
Stockholders Equity Q1 2025 · Mar 31, 2025 $2.67M
Stockholders Equity Q1 2025 · Dec 31, 2024 $4.97M
Stockholders Equity Q1 2025 · Mar 31, 2024 $9.43M
Stockholders Equity Q1 2025 · Dec 31, 2023 $12.69M
Current Liabilities Q1 2025 · Mar 31, 2025 $15.14M
Current Liabilities Q1 2025 · Dec 31, 2024 $14.63M
Total Liabilities Q1 2025 · Mar 31, 2025 $31.59M
Total Liabilities Q1 2025 · Dec 31, 2024 $31.19M
Current Assets Q1 2025 · Mar 31, 2025 $15.88M
Current Assets Q1 2025 · Dec 31, 2024 $16.6M
Total Assets Q1 2025 · Mar 31, 2025 $34.26M
Total Assets Q1 2025 · Dec 31, 2024 $36.16M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.58
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$0.96
Eps Basic Q1 2025 · Mar 31, 2025 −$0.58
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.96
Rd Expense Q1 2025 · Mar 31, 2025 $96K
Rd Expense Q1 2025 · Mar 31, 2024 $241K
Net Income Q1 2025 · Mar 31, 2025 −$2.43M
Net Income Q1 2025 · Mar 31, 2024 −$3.37M
Operating Income Q1 2025 · Mar 31, 2025 −$2.02M
Operating Income Q1 2025 · Mar 31, 2024 −$2.89M
Gross Profit Q1 2025 · Mar 31, 2025 $3.65M
Gross Profit Q1 2025 · Mar 31, 2024 $3.08M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $3.17M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $3.67M
Revenue Q1 2025 · Mar 31, 2025 $6.81M
Revenue Q1 2025 · Mar 31, 2024 $6.75M